Changeflow GovPing Government General Fagron Vancomycin Recall, 16,130 Bags, Sterilit...
Priority review Enforcement Amended Final

Fagron Vancomycin Recall, 16,130 Bags, Sterility Issue

Favicon for changeflow.com FDA Drug Recalls (Class II)
Filed
Detected
Email

Summary

FDA has classified a voluntary Class II recall of Vancomycin HCI 1.5g/250mL 0.9% Sodium Chloride Injection USP (NDC 71266-5085-01) initiated by Fagron Compounding Services of Wichita, KS. The recall affects 16,130 bags across nine lots distributed nationwide. The reason for recall is lack of assurance of sterility combined with a risk that the blue Break-Off-Part could detach from the administration port. The recall was firm-initiated on March 20, 2026 and FDA classified it on April 7, 2026.

“Vancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5085-01”

FDA , verbatim from source
Published by FDA on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

FDA classified a voluntary Class II recall of Vancomycin HCI injection from Fagron Compounding Services. The recall was initiated due to lack of assurance of sterility and a defect where the blue Break-Off-Part could detach from the administration port, affecting nine lots of product totaling 16,130 bags.

Healthcare providers and facilities that have received or administered this product should verify their inventory against the affected lot numbers (C274-000050858 through C274-000051056 with expiration dates from April 2026 through July 2026) and follow the firm's notification procedures. Pharmacies and clinical staff should check stock and quarantine any matching lots pending further guidance from Fagron or FDA.

Archived snapshot

Apr 20, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Fagron Compounding Services

Drug Recalls (Class II)

← All Drug Recalls (Class II) Class II D-0441-2026 · 20260415 · Ongoing · Voluntary: Firm initiated

Product

Vancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Services, 8710 34th St. N. Wichita, KS 67226, NDC 71266-5085-01

Reason for Recall

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Affected Lot Numbers / Codes

Lot: C274-000050858, Exp.:7/6/2026; C274-000051018, Exp.: 7/13/2026; C274-000049194, Exp.: 4/20/2026; C274-000049591, Exp.: 5/9/2026; C274-000049592, Exp.: 5/9/2026; C274-000049823, Exp.: 5/18/2026; C274-000050301, Exp.: 6/8/2026; C274-000050411, Exp.: 6/13/2026; C274-000051056, Exp.:7/18/2026.

Quantity

16,130 bags

Firm Notification Method

Letter

Distribution

Nationwide in the U.S.A.

Initiated

20260320

FDA Classified

20260407

Sources: openFDA · Raw JSON

Get daily alerts for FDA Drug Recalls (Class II)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Filed
April 15th, 2026
Instrument
Enforcement
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Compounded sterile product Sterile injection administration
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Topics
Medical Devices Product Safety

Get alerts for this source

We'll email you when FDA Drug Recalls (Class II) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!